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Summary
Haemolytic disease of the fetus and newborn (HDFN)
remains an important cause of fetal mortality with potential
neonatal and longer-term morbidity. HDFN is caused by
maternal red cell alloimmunisation, with IgG antibodies
crossing the placenta to destroy fetal erythroid cells express-
ing the involved antigen. Intrauterine fetal blood transfusion
is the therapy of choice for severe fetal anaemia. Despite a
strong evidence base and technical advances, invasive fetal
therapy carries risk of miscarriage and preterm birth. Proce-
dure-related risks are increased when invasive, in utero trans-
fusion is instituted prior to 22 weeks to treat severe early-
onset fetal anaemia. This review focuses upon this cohort of
HDFN and discusses intravenous immunoglobin (IVIg) and
novel monoclonal antibody (M281, nipocalimab) treatments
which, if started at the end of the first trimester, may attenu-
ate the transplacental passage and fetal effects of IgG anti-
bodies. Such therapy has the ability to improve fetal survival
in this severe presentation of HDFN when early in utero
transfusion may be required and may have wider implica-
tions for the perinatal management in general.
Keywords: anti-D, clinical trials, fetal medicine, fetal blood,
immune haemolytic anaemia.
Fetal anaemia has heterogeneous aetiologies and early preg-
nancy screening, recognition of risk and timely in utero treat-
ment is vital to avoid fetal death and adverse neonatal
consequences.1
Haemolytic disease of the fetus and newborn (HDFN) is a
pathologic disease process that if untreated and ameliorated,
may cause increased perinatal mortality and morbidity.2 It is
commonly caused by maternal red blood cell (RBC)
alloimmunisation, with IgG-class antibodies crossing the pla-
centa to destroy fetal erythroid cells expressing the involved
antigen. The most ‘potent’ antigens are D, Kell and c.3,4 RBC
alloantibodies are found in between 2% and 7% of the popu-
lation4,5 and over 50 different antigens may be responsible
for HDFN.6 HDFN affects 1/300–1/600 live births, as up to 1
in 80 pregnant women have clinically relevant RBC alloanti-
bodies.6–9
Approximately 15% of white European women and about
5% of women of African and Indian ancestral origin are Rh-
negative and do not express the D antigen on their RBCs.10
Incompatibility with the ‘D’ antigen of the rhesus (Rh)
group of RBC antigens is the main cause of HDFN and
despite both prenatal and postnatal anti-D prophylaxis,
approximately 1 in 1000 women still develop D alloimmuni-
sation.8 Other antigens, including ‘c’ and ‘E’ also cause
alloimmunisation and severe HDFN due to the lack of avail-
able prophylaxis.6 The ‘K’ and ‘k’ antigens of the Kell group
are a less common cause of HDFN but the fetal anaemia
associated with anti-Kell antibodies is unpredictable in onset
because antibodies cause both RBC destruction and suppres-
sion of fetal erythropoiesis.11,12
International clinical guidance exists for management of
alloimmunised pregnancies underpinned by a strong scien-
tific evidence base.13–17 In the United Kingdom, routine
antenatal maternity care ascertains the maternal ABO and
D blood group and screens alloantibody status in the first
trimester and again at 28 weeks of gestation. Women with
a previous pregnancy affected by HDFN or a critical level
of high-risk alloantibody, should be referred early in preg-
nancy to a Fetal Medicine specialist for pregnancy assess-
ment. Fetal genotype can be determined for antigens D, E,
c and K utilising cell-free fetal DNA (cffDNA) analysis with
a very high degree of sensitivity and specificity.2,18,19 Alloan-
tibody levels are usually measured four-weekly up to
28 weeks of gestation and fortnightly thereafter, so long as
they remain stable. A rapid rise in levels (doubling in a 14-
day period) or an increase above antigen-specific thresholds
will alert clinicians to a high chance of HDFN. The man-
agement of women with red cell antibodies during
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pregnancy is outside the remit of this review but has been
extensively reviewed.15
Pathophysiology
The fetal/neonatal Fc receptor (FcRn), a heterodimer, was
first identified in the neonatal rodent intestine transporting
IgG in breast milk.20 FcRn is now recognised as an important
transmembrane protein involved in IgG and albumin home-
ostasis and is present at the maternal–fetal interface (Fig 1 ).21
FcRn in vascular endothelial cells plays a major role in
immunoglobulin homeostasis by participating in the recy-
cling of the circulating serum IgG pool. Expressed by the pla-
cental syncytiotrophoblast, FcRn transports maternal IgG
subtypes across the placenta, by transcytosis, into the fetal
circulation.21 This transplacental transference is dependent
upon: (i) the maternal level of total IgG and specific antibod-
ies; (ii) gestational age of the pregnancy; (iii) placental
‘integrity’; (iv) IgG characteristics including the subclass and
degree and type of glycosylation;22 and (v) the nature of the
antigen (being more intense for thymus-dependent ones). It
is also possible that pregnancy-related pathology itself may
affect this process.23 In health, this mechanism is protective,
conferring passive immunity to the fetus and protecting IgG
from degradation. In human disease, this mechanism is
potentially harmful, such as in HDFN when alloantibodies
enter the fetal circulation to target RBCs for destruction. Pas-
sage of the IgG1 subclass is most efficient and most readily
causes HDFN.24 The IgG3 subclass anti-RBC antibodies may
also be pathogenic.25
Identification of the anaemic fetus
Direct fetal blood sampling is the gold standard for the diag-
nosis of fetal anaemia, but carries a procedure-related loss
rate of up to 2%.26–28 Doppler colour flow ultrasound to
measure the fetal middle cerebral artery peak systolic velocity
(MCA-PSV) is commonly utilised as a non-invasive
screening test with an acceptable sensitivity and specificity
for detecting (and excluding) fetal anaemia29–32 and has led
to the near disappearance of fetal hydrops at presentation.33
This has replaced the assessment of OD450 in amniotic fluid
but care should be practiced in using this screening test in
timing serial intrauterine transfusions.34 Fetal hydrops is an
abnormal collection of fluid visualised by ultrasound in two
or more body compartments (usually pericardial or pleural
effusions, ascites or skin oedema).35 It may be a characteristic
ultrasound sign of severe fetal anaemia, usually associated
with a haemoglobin deficit of greater than 70 g/l,36 high out-
put cardiac failure and associated with reduced tissue perfu-
sion and oxygenation.37 However, in the second trimester
the fetus may be severely anaemic and the association with
fetal hydrops is variable.
Invasive fetal therapy with intrauterine blood
transfusion
Since the pioneering work of Liley in New Zealand in the
1960s, when he transfused donor red blood cells into the
peritoneal cavity of an anaemic fetus in a pregnant women
with Rh(D) alloimmunisation, this fetal therapy has been uti-
lised.38 This was followed by hysterotomy direct access to the
fetal circulation39 and then Rodeck gaining direct access to
the fetal circulation by endoscopy and transfusing a baby in
utero.40 Today, the ultrasound-guided percutaneous needle
access to the umbilical cord41 or the intrahepatic vein42–44 is
relatively routine. This fetal therapy is perhaps arguably the
most successful fetal treatment administered and is associated
with low risks of miscarriage, amniorrhexis and technical
failure.45 However, it may be associated with additional
induction of maternal alloantibodies.46 The largest reported
retrospective study of 1 678 intrauterine transfusions (IUTs)
in 589 fetuses over three decades in The Netherlands showed
that routine use of fetal paralysis, the avoidance of transam-
niotic cord and umbilical arterial puncture, and a preference
for the intrahepatic route for IUT, reduced the procedure-
Fig 1. M281, a fully human, effectorless IgG1 monoclonal antibody binds competitively and with high affinity at ph 60 or ph 74 to the IgG
binding site of FcRn, a transmembrane endososomal receptor for IgG and albumin. M281 has no effect on IgM, IgA, IgE, or cellular response to
immunisation. (© Momenta Pharmaceuticals Inc. All rights reserved).
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related complication rate to 33% with a perinatal loss rate
of 18%.44 These data also support these invasive therapeutic
procedures being performed in a centre with high numbers
of cases with experience and expertise. Therefore overall, the
success of intrauterine intravascular blood transfusion is well
established with high survival and low complication rates.
Furthermore, long-term outcome in surviving children is
excellent, especially if fetal therapy is started before the onset
of hydrops.47
However, if it is necessary to perform intrauterine
intravascular transfusion before 22 weeks, the small anatomi-
cal dimensions of the fetal vasculature make the procedure
associated with higher overall fetal mortality and procedure-
related complication rates. Two small retrospective case
cohort series have demonstratd the risks of early intrauterine
transfusions.32,48 A series of thirty intrauterine transfusions
performed before 22 weeks (range 16–22 weeks) in Toronto
(with access via heterogeneous vascular sites) noted a proce-
dure-related complication rate of 67% and an overall peri-
natal loss rate of 20%.32 A case series of 29 intrauterine
transfusions performed prior to 20 weeks (range 16–
19+6 weeks) from Leiden University Medical Center in The
Netherlands48 demonstrated a procedure-related complica-
tion rate of 5% and a non-procedure-related complication
risk of 11% (per procedure). The perinatal loss rate overall
(per fetus) was 24%, with 85% of losses occurring before
20 weeks. Intrauterine transfusion in obese women
(BMI ≥ 30) prior to 20 weeks of gestation can be performed
by ultrasound-guided intracardiac puncture with comparable
outcomes when stratified for gestation.49 Others have
attempted to identify fetal anaemia early and perform fetal
intraperitoneal transfusion prior to 20 weeks, temporarily
prolonging gestation when the intrauterine fetal intravascular
transfusion will be performed.50 It is these high-risk pregnan-
cies with early-onset fetal anaemia (prior to 22 weeks) and
with high rates of procedure-related fetal loss, which would
most benefit from medical treatments to ameliorate the
alloimmune antibody effects of RBC destruction in HDFN. It
was for this reason that the UNITY study had the inclusion
criteria of previous pregnancies being severely anaemic prior
to 24 completed weeks as a subsequent pregnancy will on
average be susceptible to fetal anaemia 4–6 weeks earlier (see
below).
Fetal and neonatal morbidity and mortality
“Rhesus” alloimmunisation causes in excess of 50 000 still-
births per annum worldwide.51 In 2010, an estimated
373 300 neonates were affected by HDFN globally, although
countries with almost universal antenatal care have reduced
the prevalence to 25/100 000 live births.51 Prematurity
(mostly iatrogenic) and the presence of hydrops fetalis (at
delivery) worsens the overall outcome of these pregnancies.
Neonatal jaundice is treated with phototherapy or
exchange transfusion52 and IVIg appears limited in its role
for the neonatal management of HDFN.53 Cholestatic
Decreased Systemic IgG by blocking
maternal FcRn-dependent IgG recycling 
Seen in first-in-human study and 
expected in maternal circulaon
Blocking Maternal to fetal IgG 
transport across the placenta
Ancipated 1o mechanism for efficacy 
in pathogenic IgG-induced diseases 
of the fetus and newborn
M281 is not released into fetal circulaon
Fig 2. Schematic diagram of FcRn function and M281 blockade (adapted from Roopenian and Akilesh,21 © Momenta Pharmaceuticals Inc. All
rights reserved).
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jaundice (in 13% of neonates with HDFN) is independently
associated with IUT.54 Maternal antibodies may persist in the
neonatal circulation for up to six months, leading to ongoing
RBC destruction. Multiple neonatal top-up transfusions may
be required.52 Long-term outcomes after HDFN have been
described in a recent review.55
Maternal therapy
Potential medical therapies for alloimmunised pregnancies
must either act to: (i) reduce the amount of circulating
maternal IgG antibody (by preventing its production); (ii)
enhance its elimination from the maternal and fetal circula-
tions; (iii) prevent IgG anti-RBC antibody ‘transplacental
transport’ (due to FcRn) into the fetal circulation; iv) or alter
the interaction between the antibody and target fetal antigen.
Maternal (or fetal) immunosuppression can have life-threat-
ening side effects and a principle of fetal therapy is to min-
imise complications to the mother.56,57 In addition, such
maternal therapies may be expensive, time-consuming and
demanding on healthcare resources.
The immune system has a memory so alloimmunised
women will mount a more efficient immune response to
repeat exposure to the same RBC antigen in a future preg-
nancy, with HDFN expected to occur earlier and with
increased severity.45 Arguably the greatest need is to discover
an effective treatment for the group of high-risk pregnancies
where the early-onset disease makes them liable to undergo
multiple invasive treatments with the associated perinatal
hazards.
Maternal immunomodulation therapy
Azathioprine, promethazine and prednisolone have been pro-
posed as immunomodulatory therapies to prevent red cell
alloimmunisation58 but evidence is limited to small cohort
case series and such therapies are rarely used.59 Mouse mod-
els of ‘peptide immune therapy’ to alter the recognition of
the red cell antigens by T-helper cells to induce active toler-
ance have yielded promising results but there have been no
subsequent reports of this potential therapy.60
Plasma exchange
Maternal plasma exchange has historically been used to clear
alloantibodies from the maternal circulation but it is non-se-
lective. This leads to loss of electrolytes and important pro-
teins like coagulation factors and other immunoglobulins.
Plasmapheresis can be used in high-risk women with previ-
ous severe HDFN.61 Other concerns with this technique
relate to altered maternal haemodynamics and reduced pla-
cental perfusion as well as the impact on resources as it
requires specialist skills for vascular access and delivery. A
rebound increase in antibody levels after therapeutic plasma
exchange occurs due to immune activation as autoregulatory
factors are removed.62,63 Combining serial plasmapheresis
with IVIg infusion has been shown to reduce this problem64
and personalisation of treatment in cases of severe alloimmu-
nisation using treatment with immunoadsorption and intra-
venous IVIg has been used with good outcomes.65 This
technique is rarely now practiced in the management of sev-
ere maternal red cell alloimmunisation, certainly not often in
the UK.
Intravenous immunoglobulin (IVIg)
High-dose immunoglobulins were first used as a treatment
for autoimmune disease in 1981 when they were shown to
reduce platelet clearance in a child with immune thrombocy-
topenia.66 This therapeutic strategy is somewhat paradoxical,
as the original therapeutic use of IVIg was as an antitoxin to
treat infectious disease (before antibiotics were available) and
in immunodeficiency as replacement therapy.67
The use of maternal IVIg may postpone or even replace
invasive intrauterine transfusions in fetuses in mothers with
severe alloimmunisation in previous pregnancies.50,68 IVIg
works by diluting maternal alloantibodies, inducing competi-
tive inhibition to block the transport of IgG across the pla-
centa, increasing antibody ‘turnover’, blocking fetal
secondary macrophage function and by reducing the preg-
nant patient’s own antibody production.69,70 IVIg will not be
beneficial once HDFN has progressed to clinically significant
fetal anaemia, but initial data from case series showed a sur-
vival benefit by delaying the natural history of the condition
and ‘buying time’ to achieve a more advanced gestation.50,71–
73 However, IVIg is a derived blood product that had the
theoretical risk for infectious complications. IVIg can cause
systemic adverse reactions, such as fever, urticarial (type I
hypersensitivity) reaction, haemolytic anaemia, aseptic
meningitis, thrombosis and especially maternal headaches
which can occur in up to 15% of those receiving infusions.74
In addition, it is relatively expensive ($6 000/£4 800/€5 500
per week) therefore posing significant health economic chal-
lenges.75
The ‘Postponing Early intrauterine Transfusion with Intra-
venous immunoglobulin Treatment’ (PETIT) study was an
international collaboration, pooling multicentre, retrospective
observational cohort study data. Cases were enrolled with a
qualifying pregnancy which was affected by HDFN prior to
24 weeks and a subsequent alloimmunised pregnancy would
be affected by an antigen-positive fetus treated with or with-
out IVIg.76 The ‘treatment group’ comprised 24 women who
received IVIg (at a dose of 1 g/kg maternal weight per week).
There was a ‘control’ group of 28 women who were not trea-
ted with IVIg, and each of the 52 women also served as their
own control as outcomes in each pregnancy were compared.
Overall IVIg therapy appeared to delay the onset of clinically
significant anaemia compared to the previous pregnancy by
15 days as compared to the group not treated with IVIg
where the delay was nine days. IVIg also appeared to reduce
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the overall incidence of fetal hydrops [4% vs. 24%, odds
ratio (OR) 003; 95% confidence interval, 0–05; P = 0011]
and the need for neonatal exchange transfusion (9% vs. 37%;
OR: 01; 95% confidence interval, 005; P = 0009). Overall
survival was 88%, with no difference between groups (IVIg
or control groups).76 A subgroup analysis indicated that if
the IVIg was initiated before 13 weeks of gestation, fetal
anaemia was delayed by 25 days as compared to the previous
pregnancy. Anaemia prior to 20 weeks gestation occurred less
often (23%) as compared to the untreated previous preg-
nancy (54%).
Experimental monoclonal antibody therapy: M281
(nipocalimab) — the rationale for the clinical UNITY
study (NCT03755128)
Recently, M281, a next-generation Fc receptor (FcRn) block-
ing agent has emerged which aims to address the continued
unmet need for an effective non-surgical intervention for
pregnant mothers with HDFN, especially for those likely to
require IUT during early gestation when the procedure-re-
lated risks are relatively high.77,78 M281, also known as
nipocalimab, is a fully human, recombinant, aglycosylated
IgG1 monoclonal antibody formulated for intravenous infu-
sion. M281 binds with high affinity and specificity to the IgG
binding site of FcRn. Since FcRn mediates the transfer of
IgG from mother to fetus, M 281 has the potential to inhibit
IgG transport across the placenta including the transfer of
anti-red cell alloantibodies (Fig2). FcRn also acts to salvage
IgG from degradation during normal internalization of circu-
lating proteins into endothelial cells.21 This process of IgG
recycling maintains the long half-life of IgG and thus the
blockade of FcRn–IgG binding is expected to decrease IgG
half-life and serum concentrations including those of patho-
genic IgG.79,80 These mechanisms have also been postulated
for IVIg where high concentrations of administered IgG can
compete with endogenous IgG for placental transport and
recycling as discussed above. M281 has greater than 1 000-
fold higher affinity binding to FcRn than IgG and thus may
be much more efficient in inhibiting these processes.
In preclinical studies, M281 demonstrated inhibition of pla-
cental IgG transfer from maternal to fetal circulation in the
human placental perfusion model within 4–6 h, suggesting
rapid saturation of FcRn and a fast onset of action .81 Insignifi-
cant transfer of M281 from maternal to fetal circulation was
noted suggesting a lower risk of fetal and neonatal drug expo-
sure with maternal M281 administration (Table I). In addition,
an analogous murine anti-FcRn antibody has been reported to
protect murine fetuses from thrombocytopenia due to mater-
nal antiplatelet antibodies82 and from miscarriage due to
maternal antibodies inducing placental damage.83
M281 was well tolerated in the first-in-human study with
no serious or severe adverse events and primarily mild
adverse events with similar frequency as placebo.77 As pre-
dicted by its mechanism of action and preclinical studies,
M281 induced rapid dose-dependent lowering of serum IgG
upon administration of single and multiple doses (Fig 3). In
addition, M281 was observed to lower serum albumin albeit
to a lesser extent than for IgG, an effect that may be related
to FcRn’s role in albumin homeostasis.79 These albumin
decreases seen with M281 in human volunteers were modest
and asymptomatic. Similarly, no significant adverse effects
Fig 3. Adult healthy, non-pregnant volunteers (28 men and 22 women) received multiple doses (15 and 30 mg/kg) or placebo weekly for
four weeks. IgG levels were followed for 14 weeks in total and FcRn receptor occupancy was determined up to five weeks after the first dose.
While IgG reductions were similar for both M281 doses studied, only the 30 mg/kg dose maintained full FcRn receptor occupancy (adapted from
Ling et al.77). [Colour figure can be viewed at wileyonlinelibrary.com]
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have been noted in studies of other anti-FcRn agents in
autoimmune patients.79 In addition, early concerns regarding
increased risk of infection related to the inhibition of FcRn-
mediated lowering of IgG serum concentrations have not
been confirmed by preliminary data with M281 or other
anti-FcRn agents.79 Antagonists of FcRn do not affect other
antibody classes and in particular the IgM response to new
antigen is preserved so it is possible that the ability to fight
infection could be preserved.84 These findings confirming the
mechanism of action and tolerability of M281 and that of
similar agents support the evaluation of FcRn antagonism in
an indication such as HDFN where transfer pathogenic anti-
bodies result in severe disease and poor outcomes.
Thus in 2019, UNITY (NCT03755128), a multicentre,
open-label, proof of principle (phase II) clinical study, was ini-
tiated by clinical chief investigators, Dr Kenneth J. Moise
(University of Texas, Houston, TX, USA) and Dr Dick Oepkes
(Leiden University Medical Center, Leiden, The Netherlands),
and sponsored by Momenta Pharmaceuticals Inc. (Cambridge,
MA, USA) (Clinical Trial Gov. https://clinicaltrials.gov/ct2/
show/NCT03842189?term=M281&draw=2&rank=2).
UNITY is designed to evaluate the potential of weekly
intravenous M281 to delay or prevent the need for IUT in
pregnant mothers at risk of early-onset HDFN prior to
24 weeks, the same population analysed in the PETIT study.
M281 is initiated upon confirmation of positive fetal antigen
status at approximately 14 weeks gestation. Weekly dosing
until 35 weeks aims to block placental IgG transfer of patho-
genic alloantibodies for as long as possible. The study will
enrol 15 pregnant women affected by early-onset HDFN. Pri-
mary end-points in the study are maternal and infant safety
and efficacy as determined by the frequency of live births at
≥32 weeks gestational age without the requirement for an
IUT throughout pregnancy. Given the rarity of this patient
cohort, collaboration between international centres will be
required to attain adequate enrolment and obtain the highest
level of evidence, whilst ensuring maternal and fetal well-be-
ing and safety during the experimental phase. Robust safety
of data for this experimental therapy, including detailed
pharmacodynamic and pharmacokinetic data in pathologic
pregnancies, as well as short and long-term follow-up of sur-
viving children is mandatory.
Conclusion
Haemolytic disease of the fetus and newborn is an alloim-
mune pathology associated with an increased risk of perinatal
mortality and neonatal morbidity, both from prematurity
and the direct effects of anaemia and hyperbilirubinaemia. A
small but significant cohort of women with red cell alloim-
munisation are at risk of developing early-onset fetal anaemia
and although IUT is possible (prior to 22 weeks), it carries
increased risk of procedure-related complications including
miscarriage. In these patients, IVIg administered late in the
first trimester may postpone the gestational age when an IUT
is required to a technically safer time. A novel strategy to
inhibit transplacental alloantibody transfer with maternal
M281 monoclonal antibody therapy is under evaluation with
potential for greatest impact in these alloimmunised preg-
nancies at risk of early-onset fetal anaemia.
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Ex-vivo, dual perfusion human placental cotyledon experiments demonstrating M281 monoclonal antibody inhibits IgG transfer with minimal
M281 transfer to the fetal circulation (adapted from Roy et al.81).
Mean antipyrine fetal transfer rate for these studies was 417  27% for adalimumab alone and 438  42% for all adalimumab plus M281
studies. Fetal transfer rate = 1009 concentration of the test substance in the fetal circuit at the end of the experimental period/concentration of
the test substance in the maternal circuit at the start of the experimental period.
*Concentration of test compounds in the maternal perfusate at initiation of the experimental period.
†P values were calculated compared with no M281 using a linear mixed-effects model with random slope and intercept.
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